Placebo News and Research

RSS

CRF announces late breaking trials & first report investigations to be presented at TCT 2011

The Cardiovascular Research Foundation has announced the late breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2011 scientific symposium. Presented in partnership with the American College of Cardiology (ACC), TCT 2011 is the world’s leading educational meeting specializing in interventional cardiovascular medicine and will take place November 7-11, 2011 in San Francisco.

15 Sep 2011

Anavex Life Sciences to present data on lead compound for Alzheimer’s at Japan Neuroscience Society

Anavex Life Sciences Corp. will present the most recent data showing the therapeutic potential of ANAVEX compounds in animal models of Alzheimer’s disease at a special symposium of the 34th annual meeting of the Japan Neuroscience Society. The symposium is being held in Yokohama, Japan from September 15-17, 2011.

15 Sep 2011

Hypnosis to tackle problems of chronic pain: International expert

A visiting international rehabilitation expert has called for Hypnotic Therapy to be considered a ‘mainstream’ treatment option in the management of chronic pain, potentially benefiting thousands of Australian pain sufferers.

15 Sep 2011

Encouraging results from Alexion's eculizumab Phase 2 study on generalized myasthenia gravis

Alexion Pharmaceuticals, Inc. today announced that the Company's study of eculizumab in a small group of 14 patients with severe and refractory generalized myasthenia gravis, an ultra-rare and debilitating form of generalized myasthenia gravis (gMG), showed a strong disease improvement signal.

15 Sep 2011

SARcode Bioscience initiates enrollment in SAR 1118 Phase 3 study for dry eye disease

SARcode Bioscience, Inc., a privately-held biopharmaceutical company, announced today that the initial patient has been enrolled in the company's pivotal Phase 3 clinical study (OPUS-1) of SAR 1118 ophthalmic solution.

15 Sep 2011

Enrollment commences in ConjuChem's CJC-1134-PC Phase 2 trial for Type 2 diabetes

ConjuChem, LLC, a biotechnology company dedicated to the discovery of novel therapeutics, today announced it has initiated patient enrollment for its Phase 2 clinical trial of its proprietary GLP-1 receptor agonist drug, CJC-1134-PC, in patients with Type 2 diabetes mellitus who are receiving metformin monotherapy.

15 Sep 2011

Inovio achieves best-in-class immune responses in PENNVAX-B HIV vaccine Phase I study

Inovio Pharmaceuticals, Inc., a leader in the development of synthetic immunogens against cancers and infectious diseases, announced today that it has achieved best-in-class immune responses in a Phase I clinical study of PENNVAX-B, its product for the prevention of the HIV sub-type prevalent in the US and Europe.

14 Sep 2011

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

Pfizer Oncology announced today that data evaluating crizotinib in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), as well as data from Pfizer's renal cell carcinoma (RCC) portfolio on axitinib, an investigational compound, and SUTENT(sunitinib malate) will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden, September 23 - 27, 2011.

14 Sep 2011

Merck issues statement on GARDASIL human papillomavirus vaccine

Merck, known as MSD outside the United States and Canada, issued the following statement on GARDASIL, Merck's vaccine to protect against certain diseases caused by human papillomavirus (HPV) types 6, 11, 16 and 18.

14 Sep 2011

VIVUS presents positive results from avanafil phase 3 study in diabetics at 47th EASD meeting

VIVUS, Inc. today presented positive results from the avanafil phase 3 study in diabetics. In the REVIVE-Diabetes study (TA-302), male diabetics receiving avanafil had significant improvement in erectile function.

14 Sep 2011

A squirt of insulin up the nose for prevention of Alzheimer’s disease

Researchers have noted in a small pilot study that squirting insulin deep into the nose where it travels to the brain might hold early Alzheimer’s disease at bay. At present there are no effective ways to prevent or delay the progress of Alzheimer’s. More than 5.4 million Americans and 35 million people worldwide have Alzheimer's, the most common form of dementia.

13 Sep 2011

Researchers use MRI and PET/CT to assess safety, efficacy of heart drug dalcetrapib

Researchers from Mount Sinai School of Medicine have for the first time used several imaging techniques to prove the efficacy of a promising new treatment for atherosclerosis—the build-up of plaque in artery walls that can lead to a heart attack.

13 Sep 2011

ImmunoCellular announces updated long-term data from ICT-107 Phase I trial on GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced updated long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

13 Sep 2011

Micronutrient powder helps prevent malnutrition in children up to two years old, study review shows

In a systematic review published by the Cochrane Collaboration last week, researchers found that the micronutrient powder used in recent years to combat malnutrition, anemia and iron deficiency in children was very helpful in preventing malnutrition in children six to 24 months old, VOA News reports.

12 Sep 2011

Low-dose aspirin increases risk for GI bleeding

The risk of gastrointestinal (GI) bleeding needs to be considered when determining the potential preventive benefits associated with low-dose aspirin for cardiovascular disease and cancer.

12 Sep 2011

Sanofi's Lyxumia achieves primary efficacy endpoint in study of patients uncontrolled on metformin

Sanofi announced today that Lyxumia (lixisenatide), a once-daily GLP-1 receptor agonist under development for type 2 diabetes, achieved its primary efficacy endpoint of significant HbA1c reduction vs. placebo in patients uncontrolled on metformin.

12 Sep 2011

BioSante reports top-line results from LibiGel PK study for HSDD in postmenopausal women

BioSante Pharmaceuticals, Inc., today announced successful completion of its principal LibiGel (testosterone gel) pharmacokinetic (PK) study.

12 Sep 2011

Diamyd receives NIH grant to develop NTDDS for Chemotherapy Induced Peripheral Neuropathy

Diamyd Medical AB with collaborators has received a three million dollar grant from the US National Institutes of Health to develop the Company's patented Nerve Targeting Drug Delivery System (NTDDS) for prevention of Chemotherapy Induced Peripheral Neuropathy.

12 Sep 2011

Roche initiates Phase 1 clinical trial of investigational drug for Down syndrome

Roche today announced the initiation of its first Phase 1 clinical trial to investigate the safety and tolerability of a molecule designed to address the cognitive and behavioral deficits associated with Down syndrome.

12 Sep 2011

Auxilium reports positive data from XIAFLEX retrospective commercial patient chart review

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that positive data from a retrospective commercial patient chart review of XIAFLEX (collagenase clostridium histolyticum) used for the treatment of adult Dupuytren's contracture patients with a palpable cord are available via e-posters at the American Society for Surgery of the Hand meeting in Las Vegas.

8 Sep 2011

Placebo News and Research

CRF announces late breaking trials & first report investigations to be presented at TCT 2011

Anavex Life Sciences to present data on lead compound for Alzheimer’s at Japan Neuroscience Society

Hypnosis to tackle problems of chronic pain: International expert

Encouraging results from Alexion's eculizumab Phase 2 study on generalized myasthenia gravis

SARcode Bioscience initiates enrollment in SAR 1118 Phase 3 study for dry eye disease

Enrollment commences in ConjuChem's CJC-1134-PC Phase 2 trial for Type 2 diabetes

Inovio achieves best-in-class immune responses in PENNVAX-B HIV vaccine Phase I study

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

Merck issues statement on GARDASIL human papillomavirus vaccine

VIVUS presents positive results from avanafil phase 3 study in diabetics at 47th EASD meeting

A squirt of insulin up the nose for prevention of Alzheimer’s disease

Researchers use MRI and PET/CT to assess safety, efficacy of heart drug dalcetrapib

ImmunoCellular announces updated long-term data from ICT-107 Phase I trial on GBM

Micronutrient powder helps prevent malnutrition in children up to two years old, study review shows

Low-dose aspirin increases risk for GI bleeding

Sanofi's Lyxumia achieves primary efficacy endpoint in study of patients uncontrolled on metformin

BioSante reports top-line results from LibiGel PK study for HSDD in postmenopausal women

Diamyd receives NIH grant to develop NTDDS for Chemotherapy Induced Peripheral Neuropathy

Roche initiates Phase 1 clinical trial of investigational drug for Down syndrome

Auxilium reports positive data from XIAFLEX retrospective commercial patient chart review

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News